UBS Group AG Sells 24,463 Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)
UBS Group AG Sells 24,463 Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)
UBS Group AG reduced its stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Get Rating) by 14.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,223 shares of the company's stock after selling 24,463 shares during the quarter. UBS Group AG owned 0.84% of Global X Genomics & Biotechnology ETF worth $1,747,000 as of its most recent SEC filing.
根據最近 13F 向證券交易委員會提交的文件，瑞銀集團股份公司在第三季度將其全球 X 基因組學與生物技術 ETF（NASDAQ：GMNOM — 獲得評級）的股份減少了 14.9％。機構投資者在本季度賣出 24,463 股股票後，擁有該公司股票的 139,223 股股份。截至最近的 SEC 申請，瑞銀集團擁有 0.84% 的全球 X 基因組學及生物技術 ETF，價值 1,747,000 美元。
Other institutional investors have also added to or reduced their stakes in the company. Simplex Trading LLC lifted its position in Global X Genomics & Biotechnology ETF by 198.6% during the 3rd quarter. Simplex Trading LLC now owns 2,311 shares of the company's stock worth $29,000 after buying an additional 1,537 shares in the last quarter. Avantax Advisory Services Inc. lifted its position in Global X Genomics & Biotechnology ETF by 26.2% during the 3rd quarter. Avantax Advisory Services Inc. now owns 26,650 shares of the company's stock worth $334,000 after buying an additional 5,539 shares in the last quarter. Portland Global Advisors LLC lifted its position in Global X Genomics & Biotechnology ETF by 6.0% during the 3rd quarter. Portland Global Advisors LLC now owns 211,040 shares of the company's stock worth $2,649,000 after buying an additional 11,925 shares in the last quarter. Sightline Wealth Advisors LLC lifted its position in Global X Genomics & Biotechnology ETF by 32.9% during the 3rd quarter. Sightline Wealth Advisors LLC now owns 54,420 shares of the company's stock worth $685,000 after buying an additional 13,458 shares in the last quarter. Finally, Halbert Hargrove Global Advisors LLC bought a new stake in Global X Genomics & Biotechnology ETF during the 3rd quarter worth about $175,000. 56.95% of the stock is owned by institutional investors.
其他機構投資者也增加或減少了他們在公司的股份。單純交易有限責任公司在第三季度通過 198.6％ 提升其在全球 X 基因組學和生物技術 ETF 的地位。在上一季度額外購買 1,537 股股票後，單純交易有限責任公司現在擁有該公司股票的 2,311 股價值 29,000 美元。亞文得諮詢服務公司在第三季度將其在全球 X 基因組學和生物技術 ETF 的地位提升了 26.2％。在上一季度額外購買 5,539 股股票後，安凡得諮詢服務公司現在擁有該公司股票的 26,650 股價值 334,000 美元。波特蘭全球顧問有限責任公司在第三季度將其在全球 X 基因組學和生物技術 ETF 的地位提升了 6.0％。波特蘭全球顧問有限責任公司現在擁有該公司股票的 211,040 股，價值 2,649,000 美元，在上一季度額外購買了 11,925 股股票。視力財富顧問有限責任公司在第三季度將其在全球 X 基因組學和生物技術 ETF 的地位提升了 32.9%。視力財富顧問有限責任公司現在擁有該公司股票的 54,420 股，價值 685,000 美元，在上個季度額外購買 13,458 股股票後。最後，哈爾伯特·哈格羅夫全球顧問有限責任公司在第三季度購買了全球 X 基因組學和生物技術 ETF 的新股份，價值約為 175,000 美元。56.95％ 的股票由機構投資者擁有。
Global X Genomics & Biotechnology ETF Price Performance
全球 X 基因組學及生物科技 ETF 價格表現
Shares of NASDAQ:GNOM opened at $12.58 on Thursday. The company's 50-day moving average price is $13.16 and its two-hundred day moving average price is $13.13. Global X Genomics & Biotechnology ETF has a one year low of $10.48 and a one year high of $16.75. The stock has a market capitalization of $211.09 million, a PE ratio of -5.38 and a beta of 1.02.
納斯達克：格諾姆股份於週四開市 12.58 美元。該公司的 50 天移動平均價格為 13.16 美元，其 200 日移動平均價格為 13.13 美元。全球 X 基因組學與生物技術 ETF 擁有一年低點 10.48 美元，一年新高為 16.75 美元。該股的市值為 211.09 萬美元，私募權比率為 -5.38，測試版為 1.02。
Global X Genomics & Biotechnology ETF Profile
全球 X 基因組學及生物科技 ETF 簡介
(Get Rating)
(取得評分)
Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.
Complete Genomics, Inc 是一家生命科學公司，已開發並將脫氧核糖核酸（DNA）測序平台商業化。其完整的基因體分析平台 (CGA) 平台結合其人類基因組測序技術、先進的資訊學和資料管理軟體及其端對端的外包服務模式，為客戶提供可用於基因組研究的資料。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Global X Genomics & Biotechnology ETF (GNOM)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey's General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
- 免費獲取有關全球 X 基因組學及生物科技 ETF（GNOM）的研究報告
- META 平台可能會看到迄今為止最大的開盤新高
- 竹篙股票域高企業可能是大贏家
- 芯片設計專家新思科技是隱藏在眼前的寶石嗎？
- 你應該停放一些資本與凱西的綜合商店?
- 群眾罷工股票：雖然鐵是熱的！
Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收全球 X 基因組學及生物科技 ETF 的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Global X 基因組學和生物技術 ETF 及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。